OBJECTIVE: Permeability of blood vessels is essential for tissue homeostasis. However, disorganized hyperpermeability leads to progression of diseases. Vascular endothelial growth factor-A (VEGF) is a key regulator for leakiness of blood vessels and it has been reported that VEGF-mediated hyperpermeability was suppressed by angiopoietin-1 (Ang1). We found that Angiotensin-converting enzyme (ACE) was downregulated in endothelial cells by Ang1. ACE converts angiotensin I to angiotensin II (AII). Here, we studied the relationship between VEGF and AII relative to vascular permeability. METHODS AND RESULTS: We showed that VEGF-mediated vascular hyperpermeability was suppressed in mice given AII type 1 receptor (AT1R) blocker (ARB); the effect was also seen in AT1R-deficient mice. In this system, we found that ARB inhibited VEGF-induced gap formation. Furthermore, we ascertained that angioedema induced by overexpression of VEGF decreased noticeably in ARB-treated ischemic mice. CONCLUSIONS: Because ARB suppressed VEGF-induced vascular hyperpermeability, we propose that ARB may be used to minimize the risk of edema in therapeutic angiogenesis using VEGF.
OBJECTIVE: Permeability of blood vessels is essential for tissue homeostasis. However, disorganized hyperpermeability leads to progression of diseases. Vascular endothelial growth factor-A (VEGF) is a key regulator for leakiness of blood vessels and it has been reported that VEGF-mediated hyperpermeability was suppressed by angiopoietin-1 (Ang1). We found that Angiotensin-converting enzyme (ACE) was downregulated in endothelial cells by Ang1. ACE converts angiotensin I to angiotensin II (AII). Here, we studied the relationship between VEGF and AII relative to vascular permeability. METHODS AND RESULTS: We showed that VEGF-mediated vascular hyperpermeability was suppressed in mice given AII type 1 receptor (AT1R) blocker (ARB); the effect was also seen in AT1R-deficient mice. In this system, we found that ARB inhibited VEGF-induced gap formation. Furthermore, we ascertained that angioedema induced by overexpression of VEGF decreased noticeably in ARB-treated ischemicmice. CONCLUSIONS: Because ARB suppressed VEGF-induced vascular hyperpermeability, we propose that ARB may be used to minimize the risk of edema in therapeutic angiogenesis using VEGF.
Authors: Ahmed Y Shanab; Sally L Elshaer; Mona F El-Azab; Sahar Soliman; Harika Sabbineni; Suraporn Matragoon; Susan C Fagan; Azza B El-Remessy Journal: Angiogenesis Date: 2014-11-25 Impact factor: 9.596
Authors: Anna Kozak; Adviye Ergul; Azza B El-Remessy; Maribeth H Johnson; Livia S Machado; Hazem F Elewa; Mohammed Abdelsaid; Daniel C Wiley; Susan C Fagan Journal: Stroke Date: 2009-03-05 Impact factor: 7.914
Authors: Laila M Faddah; Nayira A Abdel Baky; Nouf M Al-Rasheed; Nawal M Al-Rasheed; Amal J Fatani; Muhammad Atteya Journal: BMC Complement Altern Med Date: 2012-05-02 Impact factor: 3.659